Status:

COMPLETED

N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

Lead Sponsor:

Unity Health Toronto

Collaborating Sponsors:

Martin, Claudio M., M.D.

Fran Priestap

Conditions:

Contrast Induced Nephropathy

Critically Ill

Eligibility:

All Genders

16+ years

Phase:

PHASE2

PHASE3

Brief Summary

Critically ill patients frequently undergo contrast enhanced computed tomography (CT) to establish diagnoses and direct management. Contrast agents can disturb kidney function and result in kidney dys...

Detailed Description

Potential participants were identified by staff intensivists or resident physicians following admission to participating ICUs. We included critically ill adult patients at least 18 years of age who co...

Eligibility Criteria

Inclusion

  • The investigators included critically ill adult patients at least 18 years of age who consented to participate in the trial, had central venous access and a foley catheter, required a contrast-enhanced CT of any organ system(s), and were considered 'at risk' for the development of CIN.
  • The investigators defined 'at risk' to include patients with at least one of the following at the time of randomization (i) a serum creatinine of \> 106 µmol/L and or urea \> 6 mmol/L, (ii) urine output of \< 0.5 cc/kg over \> 4 hrs or (iii) an increase in serum creatinine of \> 50 µmol/L in \< 24 hours.

Exclusion

  • The investigators excluded patients with a
  • CK \> 5,000 or the presence of myoglobinuria
  • a known allergy or hypersensitivity reaction to radiographic contrast dye or NAC
  • serious illness with imminent threat of dying (low likelihood of survival within 48-hours) or poor prognosis
  • pregnancy
  • patients with cardiogenic shock (NYHA class 3 or 4 symptoms)
  • known or suspected nephritic, nephrotic or pulmonary-renal syndromes
  • a post renal etiology of renal impairment
  • previous renal transplant
  • known solitary kidney
  • serum creatinine \> 200 µmol/L or (xi) recent exposure to radiographic contrast within 14 days of randomization.

Key Trial Info

Start Date :

August 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2005

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT00830193

Start Date

August 1 2002

End Date

May 1 2005

Last Update

January 27 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

London Health Sciences Centre - Victoria Hospital

London, Ontario, Canada, N6A 4G5

2

London Health Sciences Centre - University Hospital Campus

London, Ontario, Canada, N6A 5A5